Amylyx Pharmaceuticals Inc AMLX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results
Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts
Amylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences
Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026
Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum
Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference
Trading Information
- Previous Close Price
- $27.80
- Day Range
- $26.66–27.63
- 52-Week Range
- $10.85–41.13
- Bid/Ask
- $20.22 / $35.52
- Shares Outstanding
- 128.56M
- Market Cap
- $3.53B
- Volume/Avg
- 796,015 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 136
- Website
- https://www.amylyx.com
Valuation
Metric | AMLX |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.17 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
AMLX
Financial Strength
Metric | AMLX |
|---|---|
Quick Ratio | 26.44 |
Current Ratio | 26.81 |
Interest Coverage | — |
Quick Ratio
AMLX
Profitability
Metric | AMLX |
|---|---|
Return on Assets (Normalized) | −32.35% |
Return on Equity (Normalized) | −34.68% |
Return on Invested Capital (Normalized) | −37.38% |
Return on Assets
AMLX
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|X!R?jnBP | LOCK|N<?# | $72B | |||
| Teva Pharmaceutical Industries Ltd TEVA | LOCK|<b>#>l^? | LOCK|?L^^ | $51B | |||
| Haleon PLC ADR HLN | LOCK|s@NL&J | LOCK|#@ | $40B | |||
| Zoetis Inc Class A ZTS | LOCK|zGtjw$^ | LOCK|V@> | $34B | |||
| Viatris Inc VTRS | LOCK|>Zp<v%Y | LOCK|!Wq | $24B | |||
| Elanco Animal Health Inc ELAN | LOCK|?>@ | LOCK|Tm$ | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|f&qx?k | LOCK|&nW | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A HIMS | LOCK|Gm%t@> | LOCK|&%R | $4B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|%wK#WWP | LOCK|>Zkb | $2B | |||
| Perrigo Co PLC PRGO | LOCK|wxfjW? | LOCK|%!T | $2B |